Straits Times Index
3,245.97 +9.89 (+0.31%) Nikkei
27,901.01 +326.58 (+1.18%) Hang Seng
19,900.87 +450.64 (+2.32%) FTSE 100
7,476.63 +4.46 (+0.06%) BTC-USD
17,155.31 -68.84 (-0.40%) CMC Crypto 200
402.11 -4.14 (-1.02%)
Lonza Group AG (LZAGY)
| Previous close | 48.59 |
| Open | 49.23 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 48.58 - 49.40 |
| 52-week range | 43.85 - 84.16 |
| Volume | |
| Avg. volume | 160,000 |
| Market cap | 36.105B |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | 37.43 |
| EPS (TTM) | 1.30 |
| Earnings date | N/A |
| Forward dividend & yield | 0.30 (0.62%) |
| Ex-dividend date | 09 May 2022 |
| 1y target est | 89.00 |
- Reuters
Lonza's first-half core EBITDA gains 16.5%
(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.
- Reuters
Lonza's full-year core EBITDA up 20.7% on vaccine demand
(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.
